Methods in Pharmacoepidemiology / Confounding/Bias

((B-198)) (B-198) Initial-treatment Estimates as Negative Controls for Baseline Confounding Under Low Treatment Persistence: a Real-World Application to Opioids and Diverticulitis

((B-199)) (B-199) Application of methodological strategies to address unmeasured confounding in real-world vaccine safety and effectiveness study: a systematic review

((B-200)) (B-200) Assessing the Potential Differential Impact of the COVID-19 Pandemic on Cardiovascular Incidence Rates in United States Claims Data

((B-201)) (B-201) Overlap Weighting for Residual Bias Reduction in Target Trial Emulation: an Empirical Example from Re-analysis of Our Published Study

((B-202)) (B-202) Methodological Approaches to Minimizing Immeasurable Time Bias using Marginal Structural Models

((B-203)) (B-203) Aggregating and harmonizing registry databases for comparative analyses – lessons learnt

((B-204)) (B-204) Evaluation of methods for quantitative bias analysis on the impact of unmeasured confounding during planning of a single arm trial with an external comparator arm

((B-205)) (B-205) Narrative and Analytical Methods to Assess Bias and Pool Results of Studies Associated with Fall-Related Injuries

((B-206)) (B-206) Methodological Considerations about Policy Impact on Studies of Pregnancy Registries and Maternal/Infant Outcomes

((B-207)) (B-207) Random Patient Selection in Retrospective Chart Review Studies: Cases, Considerations and Insights

((B-208)) (B-208) Leveraging multiple-country data sources for a comparative drug safety study: complexities and rewards in pharmacoepidemiology

((B-209)) (B-209) Defining Cancer Outcomes Using Primary Care versus Hospitalization Data: A Case Study of GLP-1 RAs and Endometrial Cancer Incidence